Skip to ContentSkip to Navigation
About us Latest news News News articles

Alex Dömling partner in AEGIS EU Initial Training Network

18 May 2015

The EU Marie Curie Actions has awarded almost EUR 4 million to AEGIS, an Initial Training Network, to be coordinated by the Helmholtz Zentrum, München. Prof dr Alex Domling, Drug Design-group of GRIP, is one of the consortium partners in this project.

The development of effective novel drugs - especially for rare and neglected diseases - is one of the biggest challenges of the upcoming decades, as illustrated by the recent Ebola outbreak. Moreover, European innovation in new drug registrations is dramatically falling behind compared to the US and Asia. The principal aim of the AEGIS is to implement the first comprehensive, intersectoral cross-disciplinary and structured curriculum for doctoral students in the European Research Area by establishing a unique training platform for the next generation of European researchers in early drug discovery. A significant added value is provided through networking with key European pharmaceutical companies. A key research aim of AEGIS is improving the efficiency and success of early stage drug development by combining innovative methods and techniques to tackle difficult but promising targets (i.e. protein-protein interactions), as potentially valuable drug targets are often neglected due to the high risk associated with their validation. The consortium joins leading academic and industry researchers in an open innovation environment for innovative drug development in Europe. It is supported by several additional partners and stakeholders in the field.

Dömling together with Carmolex BV will perform virtual drug discovery in this network using the unique platform Instant Chemistry & ANCHOR.QUERY.

Last modified:19 February 2016 11.34 a.m.

More news